MBX Biosciences (NASDAQ:MBX) Shares Gap Down – Time to Sell?

MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) shares gapped down prior to trading on Tuesday. The stock had previously closed at $55.94, but opened at $53.28. MBX Biosciences shares last traded at $52.2280, with a volume of 19,149 shares traded.

Wall Street Analysts Forecast Growth

MBX has been the topic of a number of recent analyst reports. Stifel Nicolaus boosted their price target on shares of MBX Biosciences from $70.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Guggenheim lifted their price target on shares of MBX Biosciences from $88.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Citigroup restated a “market outperform” rating on shares of MBX Biosciences in a research report on Tuesday, October 27th. Wall Street Zen lowered MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MBX Biosciences has an average rating of “Moderate Buy” and an average target price of $87.30.

View Our Latest Stock Analysis on MBX Biosciences

MBX Biosciences Stock Performance

The firm has a fifty day simple moving average of $55.61 and a 200-day simple moving average of $46.48. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -16.75 and a beta of 0.17.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.49). Analysts expect that MBX Biosciences, Inc. will post -3.42 earnings per share for the current fiscal year.

Insider Activity at MBX Biosciences

In related news, CEO Steven Hoerter sold 4,893 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $54.82, for a total value of $268,234.26. Following the transaction, the chief executive officer directly owned 78,045 shares in the company, valued at approximately $4,278,426.90. This represents a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 31.09% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MBX. Aquatic Capital Management LLC acquired a new position in MBX Biosciences during the third quarter valued at approximately $34,000. Bellevue Group AG bought a new stake in shares of MBX Biosciences in the third quarter worth $131,000. Cetera Investment Advisers bought a new position in shares of MBX Biosciences during the third quarter worth about $257,000. HighVista Strategies LLC lifted its position in shares of MBX Biosciences by 301.5% in the 3rd quarter. HighVista Strategies LLC now owns 46,709 shares of the company’s stock worth $2,738,000 after purchasing an additional 35,075 shares during the period. Finally, First Trust Advisors LP acquired a new position in MBX Biosciences in the third quarter valued at $1,169,000.

MBX Biosciences Company Profile

(Get Free Report)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Read More

Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.